ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease

Completed

Conditions: Parkinson's Disease

First Posted Date: 2014-11-13

Last Posted Date: 2019-01-30

Lead Sponsor: AbbVie

Target Recruit Count: 62

Registration Number: NCT02289729

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
AML

Interventions: Drug: Venetoclax
Drug: Cytarabine

First Posted Date: 2014-11-10

Last Posted Date: 2022-08-29

Lead Sponsor: AbbVie

Target Recruit Count: 94

Registration Number: NCT02287233

Locations: 🇺🇸
Univ Kansas Med Ctr /ID# 131175, Kansas City, Kansas, United States
🇺🇸
Vanderbilt University Medical Center /ID# 131177, Nashville, Tennessee, United States
🇺🇸
Weill Cornell Medical College /ID# 131170, New York, New York, United States

and more 6 locations

Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis

Completed

Conditions: Respiratory Syncytial Virus (RSV)

First Posted Date: 2014-11-05

Last Posted Date: 2016-07-29

Lead Sponsor: AbbVie

Target Recruit Count: 359

Registration Number: NCT02282982

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)
Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Small Lymphocytic Lymphoma (SLL)
Acute Myeloid Leukemia (AML)

Interventions: Drug: venetoclax
Drug: azacitadine
Drug: rituximab / IDEC-C2B8

First Posted Date: 2014-10-16

Last Posted Date: 2021-08-02

Lead Sponsor: AbbVie

Target Recruit Count: 38

Registration Number: NCT02265731

Locations: 🇯🇵
Nagoya City University Hospital /ID# 129278, Nagoya shi, Aichi, Japan
🇯🇵
NHO Nagoya Medical Center /ID# 129222, Nagoya-shi, Aichi, Japan
🇯🇵
Osaka University Hospital /ID# 169862, Suita-shi, Osaka, Japan

and more 11 locations

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Phase 3

Completed

Conditions: Non-squamous Non-small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Veliparib
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2014-10-15

Last Posted Date: 2021-02-26

Lead Sponsor: AbbVie

Target Recruit Count: 595

Registration Number: NCT02264990

Locations: 🇨🇿
Multiscan s.r.o. /ID# 132689, Pardubice, Czechia
🇩🇪
Klinik Loewenstein GmbH /ID# 131925, Löwenstein, Germany
🇹🇷
Inonu University /ID# 136569, Malatya, Turkey

and more 137 locations

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)

Phase 3

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: ombitasvir/paritaprevir/ritonavir
Drug: ribavirin

First Posted Date: 2014-10-15

Last Posted Date: 2017-08-31

Lead Sponsor: AbbVie

Target Recruit Count: 184

Registration Number: NCT02265237

Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

Phase 3

Completed

Conditions: HCV
Genotype 4
Hepatitis C Infection

Interventions: Drug: 2 DAA
Drug: RBV

First Posted Date: 2014-09-25

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 160

Registration Number: NCT02247401

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

Phase 2

Completed

Conditions: HCV
Hepatitis C Virus
Chronic Hepatitis C

Interventions: Drug: ABT-493
Drug: ABT-530

First Posted Date: 2014-09-17

Last Posted Date: 2021-07-13

Lead Sponsor: AbbVie

Target Recruit Count: 174

Registration Number: NCT02243280

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Phase 2

Completed

Conditions: Hepatitis C Virus
Chronic Hepatitis C

Interventions: Drug: ABT-493
Drug: ABT-493/ABT-530
Drug: ABT-530
Drug: ribavirin (RBV)

First Posted Date: 2014-09-17

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 694

Registration Number: NCT02243293

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Phase 1

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-957
Other: Placebo for ABT-957

First Posted Date: 2014-08-20

Last Posted Date: 2021-07-06

Lead Sponsor: AbbVie

Target Recruit Count: 19

Registration Number: NCT02220738

Locations: 🇺🇸
Site Reference ID/Investigator# 129545, Glendale, California, United States
🇺🇸
Site Reference ID/Investigator# 129435, Orlando, Florida, United States
🇺🇸
Site Reference ID/Investigator# 144825, Salt Lake City, Utah, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy